Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 250 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. airzate is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 125 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. airzate is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 50 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta-2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,*initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on "as needed" reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring medication every day (see clinical trials).,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. airzate is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 0.25 mg/ml - inhalation, conventional - excipient ingredients: polysorbate 20; sodium chloride; dibasic sodium phosphate; water for injections; sorbitan monolaurate; monobasic sodium phosphate - indicationa as at 5th may 1999: adults and adolescents over 16 years of age: prophylactic management in severe asthma (patients requiring high dose inhaled or oral corticosteriod therapy. indications as at 13 july 2000: adults and adolescents over 16 years of age: prophylactic management in severe asthma (patients requiring high dose inhaled or oral corticosteroid therapy). children and adolescents from 4 to 16 years of age: treatment of mild to moderate acute exacerbations of asthma in an outpatient setting.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 1 mg/ml - inhalation, conventional - excipient ingredients: sodium chloride; water for injections; polysorbate 20; monobasic sodium phosphate; dibasic sodium phosphate; sorbitan monolaurate - indications as at 5 may 1999: adults and adolescents over 16 years of age: prophylactic management in severe asthma (patients requiring high dose inhaled or oral corticosteriod therapy. indications as at 13 july 2000: adults and adolescents over 16 years of age: prophylactic management in severe asthma (patients requiring high dose inhaled or oral corticosteroid therapy). children and adolescents from 4 to 16 years of age: treatment of mild to moderate acute exacerbations of asthma in an outpatient setting.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salbutamol sulfate, quantity: 6 mg (equivalent: salbutamol, qty 5 mg) - inhalation, conventional - excipient ingredients: water for injections; sodium chloride; sulfuric acid - for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise induced asthma or in other situations known to induce bronchospasm.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salbutamol sulfate, quantity: 3 mg (equivalent: salbutamol, qty 2.5 mg) - inhalation, conventional - excipient ingredients: water for injections; sulfuric acid; sodium chloride - for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise induced asthma or in other situations known to induce bronchospasm.

Canada - English - Health Canada

glaxosmithkline inc - salbutamol (salbutamol sulfate) - metered-dose aerosol - 100mcg - salbutamol (salbutamol sulfate) 100mcg - selective beta 2-adrenergic agonists

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 1 mg/ml (plus 0.2mg/ml overage);   - solution for inhalation - 2.5mg/2.5ml - active: salbutamol sulfate 1 mg/ml (plus 0.2mg/ml overage)   excipient: sodium chloride sulfuric acid water for injection - salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. for patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failure to respond promptly or fully to such rescue medication signals a need for urgent medical advice and treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 2 mg/ml (plus 0.4mg/ml overage);   - solution for inhalation - 5mg/2.5ml - active: salbutamol sulfate 2 mg/ml (plus 0.4mg/ml overage)   excipient: sodium chloride sulfuric acid water for injection - salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. for patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failure to respond promptly or fully to such rescue medication signals a need for urgent medical advice and treatment.